MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Cellectar Biosciences Net Income 2011-2025 | CLRB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cellectar Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.8 M | -31.8 M | -24.1 M | -15.1 M | -14.1 M | -13.2 M | -13.6 M | -6.18 M | -5.5 M | -8.11 M | -10.8 M | -8.8 M | -7.44 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.5 M | -42.8 M | -15.5 M |
Quarterly Net Income Cellectar Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.44 M | -5.45 M | -6.6 M | - | -14.7 M | -919 K | -26.6 M | - | -17.5 M | -10.2 M | -8.58 M | - | -7.81 M | -7.44 M | -6.14 M | - | -5.82 M | -6.03 M | -6.36 M | - | -3.91 M | -3.61 M | -3.96 M | - | -3.9 M | -3.19 M | -3.62 M | - | -3.01 M | -2.92 M | -3.48 M | - | -3.47 M | -3.12 M | -2.89 M | - | -2.29 M | -2.13 M | 825 K | - | -1.86 M | -2.29 M | -2.3 M | - | 324 K | -2.09 M | -2.94 M | - | -1.32 M | -2.06 M | -3.45 M | - | -2.05 M | -2.23 M | -2.36 M | - | -1.91 M | -2.6 M | -965 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 825 K | -26.6 M | -4.65 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
-22 M | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-72.8 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-132 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
BioVie
BIVI
|
-17.5 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
115 M | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Axon Enterprise
AXON
|
377 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
1.63 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
-8.8 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-847 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Enochian Biosciences
ENOB
|
-178 M | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
-20.9 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 9.15 | -0.44 % | $ 1.47 B | Britain |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
-8.95 B | $ 51.05 | -0.32 % | $ 103 B | USA |
 |
Abeona Therapeutics
ABEO
|
-54.2 M | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-40.4 M | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-59.6 M | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
-238 M | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 3.22 | -2.72 % | $ 908 M | Israel |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - | Russia |